This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Murphy, M. G. Articles by Gertz, B. J. Search for Related Content PubMed PubMed Citation Articles by Murphy, M. G. Articles by Gertz, B. J.

Effect of Alendronate and MK-677 (a Growth Hormone Secretagogue), Individually and in Combination, on Markers of Bone Turnover and Bone Mineral Density in Postmenopausal Osteoporotic Women¹

Merck Research Laboratories (M.G.M., K.C., J.C., S.R., D.K., B.J.G.), Rahway, New Jersey 07065-0900; San Diego Endocrine and Medical Clinic (S.W.), San Diego, California 92108; Oregon Osteoporosis Center (M.M.), Portland, Oregon 07213; Rush-Presbyterian St. Lukes Medical Center (T.S.), Chicago, Illinois 60612

Address all correspondence and requests for reprints to: M. Gail Murphy, M.D., Merck Research Laboratories, Building 10, Sentry Parkway, Bluebell, Pennsylvania 19422. E-mail: gail_murphy{at}merck.com

GH increases bone turnover and stimulates osteoblast activity. We hypothesized that administration of MK-677, an orally active GH secretagogue, together with alendronate, a potent inhibitor of bone resorption, would maintain a higher bone formation rate relative to that seen with alendronate alone, thereby generating greater enhancement of bone mineral density (BMD) in women with postmenopausal osteoporosis. We determined the individual and combined effects of MK-677 and alendronate administration on insulin-like growth factor I levels and biochemical markers of bone formation (osteocalcin and bone-specific alkaline phosphatase) and resorption [urinary N-telopeptide cross-links (NTx)] for 12 months and BMD for 18 months.

In a multicenter, randomized, double blind, placebo-controlled, 18-month study, 292 women (64–85 yr old) with low femoral neck BMD were randomly assigned in a 3:3:1:1 ratio to 1 of 4 daily treatment groups for 12 months: MK-677 (25 mg) plus alendronate (10 mg); alendronate (10 mg); MK-677 (25 mg); or a double dummy placebo. Patients who received MK-677 alone or placebo through month 12 received MK-677 (25 mg) plus alendronate (10 mg) from months 12–18. All other patients remained on their assigned therapy. All patients received 500 mg/day calcium.

The primary results, except for BMD, are provided for month 12. MK-677, with or without alendronate, increased insulin-like growth factor I levels from baseline (39% and 45%; P < 0.05 vs. placebo). MK-677 increased osteocalcin and urinary NTx by 22% and 41%, on the average, respectively (P < 0.05 vs. placebo). MK-677 and alendronate mitigated the reduction in bone formation compared with alendronate alone based on mean relative changes in serum osteocalcin (-40% vs. -54%; P < 0.05, combination vs. alendronate) and reduced the effect of alendronate on resorption (NTx) as well (-52% vs. -61%; P < 0.05, combination vs. alendronate). MK-677 plus alendronate increased BMD at the femoral neck (4.2% vs. 2.5% for alendronate; P < 0.05). However, similar enhancement was not seen with MK-677 plus alendronate in BMD of the lumbar spine, total hip, or total body compared with alendronate alone. GH-mediated side effects were noted in the groups receiving MK-677, although adverse events resulting in discontinuation from the study were relatively infrequent. In conclusion, the anabolic effect of GH, as produced through the GH secretagogue MK-677, attenuated the indirect suppressive effect of alendronate on bone formation, but did not translate into significant increases in BMD at sites other than the femoral neck. Although the femoral neck is an important site for fracture prevention, the lack of enhancement in bone mass at other sites compared with that seen with alendronate alone is a concern when weighed against the potential side effects of enhanced GH secretion.

This article has been cited by other articles:

				R. Nass, S. S. Pezzoli, M. C. Oliveri, J. T. Patrie, F. E. Harrell Jr., J. L. Clasey, S. B. Heymsfield, M. A. Bach, M. L. Vance, and M. O. Thorner Effects of an Oral Ghrelin Mimetic on Body Composition and Clinical Outcomes in Healthy Older Adults: A Randomized Trial Ann Intern Med, November 4, 2008; 149(9): 601 - 611. [Abstract] [Full Text] [PDF]

				A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF]

				H. Ariyasu, H. Iwakura, G. Yamada, K. Nakao, K. Kangawa, and T. Akamizu Efficacy of Ghrelin as a Therapeutic Approach for Age-Related Physiological Changes Endocrinology, July 1, 2008; 149(7): 3722 - 3728. [Abstract] [Full Text] [PDF]

				Y. Sun, J. M. Garcia, and R. G. Smith Ghrelin and Growth Hormone Secretagogue Receptor Expression in Mice during Aging Endocrinology, March 1, 2007; 148(3): 1323 - 1329. [Abstract] [Full Text] [PDF]

				H. Jiang, L. Betancourt, and R. G. Smith Ghrelin Amplifies Dopamine Signaling by Cross Talk Involving Formation of Growth Hormone Secretagogue Receptor/Dopamine Receptor Subtype 1 Heterodimers Mol. Endocrinol., August 1, 2006; 20(8): 1772 - 1785. [Abstract] [Full Text] [PDF]

				B. Holst, E. Brandt, A. Bach, A. Heding, and T. W. Schwartz Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling Mol. Endocrinol., September 1, 2005; 19(9): 2400 - 2411. [Abstract] [Full Text] [PDF]

				R. G. Smith Development of Growth Hormone Secretagogues Endocr. Rev., May 1, 2005; 26(3): 346 - 360. [Abstract] [Full Text] [PDF]

				R. G. Smith, L. Betancourt, and Y. Sun Molecular Endocrinology and Physiology of the Aging Central Nervous System Endocr. Rev., April 1, 2005; 26(2): 203 - 250. [Abstract] [Full Text] [PDF]

				A. J. van der Lely, M. Tschop, M. L. Heiman, and E. Ghigo Biological, Physiological, Pathophysiological, and Pharmacological Aspects of Ghrelin Endocr. Rev., June 1, 2004; 25(3): 426 - 457. [Abstract] [Full Text] [PDF]

				Y. Sun, S. Ahmed, and R. G. Smith Deletion of Ghrelin Impairs neither Growth nor Appetite Mol. Cell. Biol., November 15, 2003; 23(22): 7973 - 7981. [Abstract] [Full Text] [PDF]

				N. M. Thompson, J. S Davies, A. Mode, P. A. Houston, and T. Wells Pattern-Dependent Suppression of Growth Hormone (GH) Pulsatility by Ghrelin and GH-Releasing Peptide-6 in Moderately GH-Deficient Rats Endocrinology, November 1, 2003; 144(11): 4859 - 4867. [Abstract] [Full Text] [PDF]